NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Voyager Earn Accounts and VGX tokens (“Voyager Investment Products”) between January 1, 2020 and November 9, 2022, inclusive (the “Class Period”), against Stephen Ehrlich, Gerard Hanshe, David Brosgol, Janice Barrilleaux, Philip Eytan, Jarrett Lilien, and Brian Brooks (together, “Defendants”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 10, 2023.
SO WHAT: If you purchased Voyager Earn Accounts and/or VGX tokens during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Voyager class action, go to https://rosenlegal.com/submit-form/?case_id=9827 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 10, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, Defendants violated provisions of the Securities Act by selling non-exempt securities without registering them. The complaint alleges that Defendants participated in Voyager’s failure to register the Voyager Financial Products. After plaintiffs and class members purchased Voyager Financial Products, the complaint alleges that Voyager suspended withdrawals from its platform.
To join the Voyager class action, go to https://rosenlegal.com/submit-form/?case_id=9827 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
- Anti-Static Films Market Size to Surpass USD 767.66 Million by 2030 at 4.57% CAGR – Report by Market Research Future (MRFR) - December 2, 2022
- Black Masterbatch Market Worth USD 3,263.1 Million by 2030 Witnessing a CAGR of 5.14% – Report by Market Research Future (MRFR) - December 2, 2022
- Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201 - December 2, 2022